Navigation Links
Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease

Investigators report safety findings and statistically significant improvements in clinical measures of movement, PET Scans at 19th Annual Symposia on the Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement DisordersNeurologix's Phase I trial showed positive interim results in patients with Parkinson's disease. One year following treatment, patients exhibited a statistically significant improvement in motor function on the side of their body correlating to the treated part of the brain. Further, PET scans at one year revealed that the treated side of the brain exhibited a statistically significant decrease in abnormal metabolism, results considered similar to those achieved with STN Deep Brain Stimulation.

FORT LEE, N.J., Sept. 26, 2005 -- Neurologix, Inc. (OTCBB:NRGX) today announced positive interim results of its landmark gene therapy clinical trial for patients with Parkinson's disease. Neurologix's 12-patient, dose-escalating Phase I trial is the world's first study to use a viral vector (the non-pathogenic adeno-associated virus, or AAV) for the treatment of an adult neurological disease. In the Neurologix-funded trial, the vector was injected into a specific target site in the brain in order to transfer a gene to treat Parkinson's disease. The gene encodes glutamic acid decarboxylase (GAD), an enzyme which synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA).

Under the FDA-sanctioned trial protocol, patients with advanced Parkinson's disease received unilateral (one side of the brain) infusion of AAV-GAD via a hair-thin catheter into the subthalamic nucleus (STN), a deep brain structure known to function abnormally in Parkinson's patients. According to the interim findings, Neurologix's STN AAV-GAD treatment appears to be safe and well-tolerated in advanced Parkinson's disease, with no evidence of adverse effects or immunologic reaction related to the study treatment.
'"/>

Source:jjackson@burnsmc.com


Page: 1 2 3 4 5 6

Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
4. GlycoFi announces the first production of antibodies with human glycosylation in yeast
5. NHGRI announces new sequencing targets
6. CHAVI announces international search for genes affecting HIV response
7. NHGRI announces latest sequencing targets
8. MUHC announces a transplant first in Quebec
9. St. Jude announces breakthrough in eye cancer treatment
10. NIH announces phase III clinical trial of creatine for Parkinsons disease
11. Insight into the processes of positive and negative learners
Post Your Comments:
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
(Date:3/18/2015)... , March 18, 2015 As mobile ... new revolutionary smart wallets and apps continue to be introduced ... entrenched in the mobile payment industry in focus today are:  ... Ltd. (NYSE: BABA ), Apple Inc. (NASDAQ: ... and Facebook Inc. (NASDAQ: FB ) ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... the University of Kentucky have discovered that plasminogen, a protein ... up the progress of prion diseases such as mad cow ... for the development of drugs to treat prion diseases in ... researcher at the UK Sanders-Brown Center on Aging and professor ...
... - (Jan. 10, 2011) All fat cells are not ... understanding and treatment of type 2 diabetes and obesity, said ... a report that appears in the current issue of the ... The amount of fat in each cell and the central ...
... 10, 2011 Based on its recent analysis ... Sullivan recognizes Cardiocom with the 2011 North American ... provides integrated clinical telehealth services that offer significant ... (Logo:   http://photos.prnewswire.com/prnh/20081117/FSLOGO ) Cardiocom combines ...
Cached Biology News:Research identifies drug target for prion diseases, 'mad cow' 2Single cell studies identify coactivator role in fat cell maturation 2Single cell studies identify coactivator role in fat cell maturation 3Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 2Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 3Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 4
(Date:4/17/2015)... 17, 2015 CIO Review ( http://www.cioreview.com ... 20 Most Promising Pharma and Life Science Technology Solution ... global compliance software platform for life sciences companies. ... a panel of experts and members of CIO Review’s ... MediSpend Platform has been on our radar for some ...
(Date:4/17/2015)... , April 17, 2015  Guggenheim Securities, the ... today announced the hiring of William Tanner ... Mr. Tanner will start work at Guggenheim ... York office. "Bill brings a ... research, to our experienced and highly acclaimed healthcare team," ...
(Date:4/17/2015)... 2015 Global Stem Cells Group ... Cell Summit 2015 April 27 - 29, 2015 in ... in all areas of stem cell research including applications, ... and regenerative medicine. , The conference will address ... as translational research in stem cell therapies, regenerative medicine, ...
(Date:4/17/2015)... April 17, 2015 BellBrook Labs ... marketing support for the powerful Orthogonal Pooled Screening ... Genomics Center at the Lankenau Institute for Medical ... is to measurably improve successful drug discovery outcomes ... offering rare, drug-like libraries available nowhere else, coupled ...
Breaking Biology Technology:MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2
... Calif., Nov. 13 AMDL, Inc. (Amex:,ADL) reported today ... Securities and,Exchange Commission indicating that its Form 10-QSB for ... filed by November 14, 2007. However,AMDL expects to file ... time,allotted by the Rules. Gary L. Dreher, President, stated: ...
... Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) ... announced that the Company,s,exclusive distributor in Italy, CTLM ... and other international sites at the 4th,Attualita in ... http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ) IMDS expects Italy ...
... MEDICA is the world,s,leading medical industry trade ... November 14th-17th, to present new advances and,technologies for ... medical devices go beyond possessing Europe,s,largest market and ... government is working to enhance research and development ...
Cached Biology Technology:AMDL Announces Filing of Extension on Third Quarter 2007 Form 10-QSB 2Imaging Diagnostic Systems Exhibits CT Laser Breast Imaging Results at Major Italian Multidisciplinary Breast Cancer Meeting 2Germany Hosts World Leading Medical Industry Fair 2
... Experion HighSens reagents and supplies, ... and supplies sufficient to perform high-sensitivity ... chips on the Experion automated electrophoresis ... gel, 20 microliters RNA HighSens stain, ...
...
... BIP-NC H-IPMIK-OH Lyophilized solid. ... LIGHT. HYGROSCOPIC. PACKAGED UNDER INERT GAS. A ... V5 (Cat. No. 196810) that serves as ... apoptosis (~200 μM). Purity: ≥97% by ...
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
Biology Products: